glp 1 drugs microdosing More Than a Third of

#BMS #Cobenfy #schizophrenia #psychiatry Biotech Executive, Thought Leader & Creator | Diagnostics Executive | Microfluidics & Immunoassay Innovation | FDA Strategy Led EUA 230055, EUA 240006 & 510(k) K240728 | Oncology, AIBiology & IVD Commercialization Market Watch | Bristol Myers Squibbs Cobenfy Faces Uptake Challenges Amid Strong Q3 Earnings Bristol Myers Squibb ($BMY) reported $12.2B in Q3 revenue, surpassing analyst expectations yet investor attention centered on Cobenfy, the first new schizophrenia drug in 35 years, which posted $43M in sales, slightly below forecasts

Drug or Food Interactions Delayed gastric emptying may impact absorption of concomitantly administered oral medications

These are prescription medications engineered to mimic or enhance GLP-1, lasting far longer in the body than natural GLP-1 (which disappears in 12 minutes)

Newcomers often look for a gentle on-ramp to explore features without rushing

Under sustained reductions in nutrient inflow, metabolic reserve may narrow as reduced substrate availability limits mitochondrial redox regeneration and constrains the capacity to match oxidative flux with regenerative turnover